Predictive biomarkers to anti-VEGF therapy: progress toward an elusive goal.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23386694.
- Also identified by DOI 10.1158/1078-0432.CCR-12-3585 and PMC identifier 3580199.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The search for reliable biomarkers predictive of response to anti-VEGF therapy has been elusive. VEGF-A, the therapeutic target of bevacizumab, is an intuitive candidate as a predictive biomarker to bevacizumab-based anticancer therapy. However, there remains much controversy in the use of VEGF-A as a predictor of response to bevacizumab.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Biomarkers, Tumor
- Carcinoma, Renal Cell
- Colorectal Neoplasms
- Lung Neoplasms
- Vascular Endothelial Growth Factor A